Skip Navigation

skip navigationNIDDK Home
NIDDK Reference Collection
Diet   Exercise   Health  
Home Page
-  

FAQ

Detailed Search

- -
NIDDK INFORMATION SERVICES
- -

Diabetes

Digestive Diseases

Endocrine and Metabolic Diseases

Hematologic Diseases

Kidney and Urologic Diseases

Weight-control Information Network

-
NIDDK EDUCATION
PROGRAMS

- -

National Diabetes Education Program

National Kidney Disease Education Program

-
- - -
NIDDK Home
-
Contact Us
-
New Search
-
Topic: diabetes (dm)
Title: Coming of Age for the Incretins.
Author: Holst, J.J.; Deacon, C.F.
Source: IN: LeRoith, D.; Vinik, A., eds. Controversies in Treating Diabetes: Clinical and Research Aspects. Totowa, NJ: Humana Press.2008. pp 269-290.
Abstract: This chapter about the incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), is from a book that addresses diabetes controversies, specifically in the etiology and management of the disease. The authors of this chapter consider the role of these incretin hormones in postprandial insulin secretion, which is insulin secretion that happens after a meal. They note that, in type 2 diabetes, the incretin effect is severely reduced. Substitution therapy with GLP-1 can result in glucose-induced insulin secretion, up-regulation of insulin and other beta-cell genes, stimulation of beta-cell proliferation, neogenesis and inhibition of beta-cell destruction, inhibition of glucagon secretion, inhibition of gastric emptying, and inhibition of appetite and food intake. However, GLP-1 is rapidly destroyed by an enzyme called dipeptidyl peptidase IV (DPP-IV), so any drug therapy that uses GLP-1 will require orally active DPP-IV inhibitors. The authors describe the animal studies and clinical trials that have focused on these incretins. One GLP-1 receptor activator (Byetta) and one of the DPP-IV inhibitors are already on the market and other compounds are in late phases of development or awaiting approval. 110 references.

Format: Book Chapter
Language: English.
Major Keywords: Diabetes Mellitus. Controversial Therapy. Patient Care Management. Postprandial Hyperglycemia. Drug Therapy. Pathophysiology. Incretin Mimetics.
Minor Keywords: DPP-IV Inhibitors. Gastrointestinal Motility. Gastric Emptying. Exenatide. Glucagon. Insulin. Physiology. Drug Effects. Clinical Trials.
Publication Number: DMBK13267
Printer-Friendly Version | Return to Search Results
<-- previous record | next record -->

View NIDDK Publications | NIDDK Health Information | Contact Us

The NIDDK Reference Collection is a service of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.
NIDDK Clearinghouses Publications Catalog
5 Information Way
Bethesda, MD 20892–3568
Phone: 1–800–860–8747
TTY: 1–866–569–1162
Fax: 703–738–4929
Email: catalog@niddk.nih.gov

Privacy | Disclaimers | Accessibility | Public Use of Materials
H H S logo - link to U. S. Department of Health and Human Services NIH logo - link to the National Institute of Health NIDDK logo - link to the National Institute of Diabetes and Digestive and Kidney Diseases